Which groups of people are not suitable to use Roprostim (Wilning) and medication warnings

Roplastin is a thrombopoietin receptor agonist, mainly used for the treatment of immune thrombocytopenia (ITP) in adults or children, but it is not suitable for all patients. First of all, those who are known to be allergic to this drug or preparation ingredients should strictly avoid using it to avoid allergic reactions or even severe anaphylactic shock. Secondly, it is not recommended for patients with active thrombotic diseases (such as deep vein thrombosis, pulmonary embolism) or long-term hypercoagulable state, because loprostim will promote the increase of platelets and further increase the risk of thrombosis.

In addition, for patients with myelofibrosis or obvious bone marrow structural abnormalities, the use of loprostim should be treated with special caution or avoidance. The drug may cause reversible bone marrow reticular fibroplasia, which may further aggravate bone marrow damage in patients with already unstable bone marrow function. If the patient has anemia, leukopenia and other multi-lineage cell abnormalities, bone marrow evaluation must be performed before considering whether it can be used, so as not to cover up the essential problems of other blood diseases.

In addition, for patients with malignant tumors who are receiving chemotherapy, Roprostim cannot replace whitening or redness-raising treatment, and it is not suitable for all treatment options. Data show that TPO receptor agonists may stimulate the growth of abnormal cells in the context of certain tumors, so they are clinically more inclined to be used in patients with a clear diagnosis of ITP and no tumor-related thrombocytopenia. If it is secondary thrombocytopenia (such as bone marrow suppression, infection and other factors), loprostim often cannot fundamentally solve the problem.

There are several key safety warnings that need to be paid attention to while using Roprostim: First, the platelet count needs to be monitored regularly to avoid platelets rising too high and causing thrombosis. Second, platelets may drop rapidly after stopping the drug, even lower than the baseline, so the drug withdrawal strategy requires gradual adjustment of the dose under the guidance of a doctor. Third, if abnormal symptoms such as headache, chest pain, limb swelling, difficulty breathing, etc. occur, you should seek medical treatment promptly to investigate thrombosis events. In short, although Roprostim is an important treatment option for ITP, the applicable population needs to be strictly screened and used under the guidance of professional doctors.

Reference materials:https://www.drugs.com/